Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine
Simple Summary
Chanias, I.; Stojkov, K.; Stehle, G.T.; Daskalakis, M.; Simeunovic, H.; Njue, L.M.; Schnegg-Kaufmann, A.S.; Porret, N.A.; Allam, R.; Rao, T.N.; Benz, R.; Ruefer, A.; Schmidt, A.; Adler, M.; Rovo, A.; Balabanov, S.; Stuessi, G.; Bacher, U.; Bonadies, N., on behalf of the Swiss MDS Study Group. Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. Cancers 2021, 13, 3296. https://doi.org/10.3390/cancers13133296
Chanias I, Stojkov K, Stehle GT, Daskalakis M, Simeunovic H, Njue LM, Schnegg-Kaufmann AS, Porret NA, Allam R, Rao TN, Benz R, Ruefer A, Schmidt A, Adler M, Rovo A, Balabanov S, Stuessi G, Bacher U, Bonadies N on behalf of the Swiss MDS Study Group. Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. Cancers. 2021; 13(13):3296. https://doi.org/10.3390/cancers13133296
Chicago/Turabian StyleChanias, Ioannis, Kristina Stojkov, Gregor Th. Stehle, Michael Daskalakis, Helena Simeunovic, Linet Muthoni Njue, Annatina S. Schnegg-Kaufmann, Naomi A. Porret, Ramanjaneyulu Allam, Tata Nageswara Rao, Rudolf Benz, Axel Ruefer, Adrian Schmidt, Marcel Adler, Alicia Rovo, Stefan Balabanov, Georg Stuessi, Ulrike Bacher, and Nicolas Bonadies on behalf of the Swiss MDS Study Group. 2021. "Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine" Cancers 13, no. 13: 3296. https://doi.org/10.3390/cancers13133296